AstraZeneca Pharma India (ASTRAZEN) Fundamentals 2026 — P/E 107.1x, Revenue Analysis | SniperIQ
AstraZeneca Pharma India (ASTRAZEN) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹20,085 Crore, trading at ₹8033.05 on the BSE. This SniperIQ fundamentals page covers AstraZeneca Pharma India's valuation (P/E 107.1x, P/B 23.0x), profitability (net margin 8.2%), revenue (₹2,276 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is AstraZeneca Pharma India's market cap?
AstraZeneca Pharma India (ASTRAZEN) has a market capitalization of approximately ₹20,085 Crore, trading at ₹8033.05 on the BSE. Market cap moves with the live share price.
What is AstraZeneca Pharma India's P/E ratio?
AstraZeneca Pharma India's trailing twelve-month P/E ratio is 107.1x, with a price-to-book (P/B) of 23.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is AstraZeneca Pharma India?
AstraZeneca Pharma India runs a net profit margin of 8.2%, a gross margin of 37.1%, and an operating margin of 10.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does AstraZeneca Pharma India generate?
AstraZeneca Pharma India reported revenue of ₹2,276 Crore for fiscal year 2026, with net income of ₹188 Crore and earnings per share (EPS) of 75.01. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does AstraZeneca Pharma India pay a dividend?
AstraZeneca Pharma India offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is AstraZeneca Pharma India financially healthy?
AstraZeneca Pharma India carries a debt-to-equity ratio of 0.13x and a current ratio of 1.77x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is AstraZeneca Pharma India a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For AstraZeneca Pharma India (ASTRAZEN) the key facts are: market cap ₹20,085 Crore, P/E 107.1x, revenue ₹2,276 Crore, 52-week range 7630-9850. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track AstraZeneca Pharma India's full fundamentals live
Get AstraZeneca Pharma India's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.